IN2012DN03182A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03182A
IN2012DN03182A IN3182DEN2012A IN2012DN03182A IN 2012DN03182 A IN2012DN03182 A IN 2012DN03182A IN 3182DEN2012 A IN3182DEN2012 A IN 3182DEN2012A IN 2012DN03182 A IN2012DN03182 A IN 2012DN03182A
Authority
IN
India
Prior art keywords
compounds
disclosed
methods
intermediates
synthesis
Prior art date
Application number
Other languages
English (en)
Inventor
Chakrapani Subramanyam
Travis T Wager
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of IN2012DN03182A publication Critical patent/IN2012DN03182A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IN3182DEN2012 2009-10-28 2010-10-20 IN2012DN03182A (en:Method)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25550609P 2009-10-28 2009-10-28
PCT/IB2010/054749 WO2011051858A1 (en) 2009-10-28 2010-10-20 Imidazole derivatives as casein kinase inhibitors

Publications (1)

Publication Number Publication Date
IN2012DN03182A true IN2012DN03182A (en:Method) 2015-09-25

Family

ID=43301770

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3182DEN2012 IN2012DN03182A (en:Method) 2009-10-28 2010-10-20

Country Status (22)

Country Link
US (1) US8518944B2 (en:Method)
EP (1) EP2493876B1 (en:Method)
JP (1) JP5784620B2 (en:Method)
KR (1) KR101421852B1 (en:Method)
CN (1) CN102686580B (en:Method)
AR (1) AR078797A1 (en:Method)
AU (1) AU2010311035B2 (en:Method)
CA (1) CA2777632C (en:Method)
DK (1) DK2493876T3 (en:Method)
ES (1) ES2460065T3 (en:Method)
HR (1) HRP20140252T1 (en:Method)
IL (1) IL219190A0 (en:Method)
IN (1) IN2012DN03182A (en:Method)
MX (1) MX2012004997A (en:Method)
PL (1) PL2493876T3 (en:Method)
PT (1) PT2493876E (en:Method)
RS (1) RS53246B (en:Method)
SI (1) SI2493876T1 (en:Method)
TW (1) TW201125864A (en:Method)
UY (1) UY32977A (en:Method)
WO (1) WO2011051858A1 (en:Method)
ZA (1) ZA201202776B (en:Method)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007334260A1 (en) 2006-11-15 2008-06-26 Massachusetts Eye & Ear Infirmary Generation of inner ear cells
WO2012085721A1 (en) * 2010-12-20 2012-06-28 Pfizer Inc. Novel fused pyridine compounds as casein kinase inhibitors
AU2013312358B2 (en) 2012-09-07 2018-08-09 Massachusetts Eye & Ear Infirmary Treating hearing loss
WO2014100533A1 (en) 2012-12-21 2014-06-26 Bristol-Myers Squibb Company NOVEL SUBSTITUTED IMIDAZOLES AS CASEIN KINASE 1 δ/ε INHIBITORS
EP3006438A4 (en) * 2013-05-30 2017-01-18 Sumitomo Dainippon Pharma Co., Ltd. Cyclic aminomethyl pyrimidine derivative
SG11201606427SA (en) 2014-02-07 2016-09-29 Agency Science Tech & Res 2,4,5-tri-substituted azole-based casein kinase 1 inhibitors as inducers for cardiomyogenesis
WO2016022776A2 (en) 2014-08-06 2016-02-11 Massachusetts Eye And Ear Infirmary Increasing atoh1 life to drive sensorineural hair cell differentiantion
FI3273955T3 (fi) * 2015-03-23 2025-12-12 Tianli Biotech Pty Ltd Hengityselinsairauksien hoito
US11185536B2 (en) * 2015-12-04 2021-11-30 Massachusetts Eye And Ear Infirmary Treatment of hearing loss by inhibition of casein kinase 1
AU2017212655B2 (en) 2016-01-29 2024-01-18 Decibel Therapeutics, Inc. Expansion and differentiation of inner ear supporting cells and methods of use thereof
PT3619204T (pt) * 2017-05-03 2025-10-29 Tianli Biotech Pty Ltd Compostos para o tratamento de doenças respiratórias
US10973820B2 (en) 2017-12-13 2021-04-13 Facio Intellectual Property B.V. Compounds for treatment of diseases related to DUX4 expression
MX2021002652A (es) * 2018-09-09 2021-09-23 Qanatpharma Ag Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
WO2020093097A1 (en) * 2018-11-07 2020-05-14 The University Of Melbourne Compounds and compositions for the treatment of respiratory diseases
TW202112368A (zh) 2019-06-13 2021-04-01 荷蘭商法西歐知識產權股份有限公司 用於治療有關dux4表現之疾病的抑制劑組合
WO2021190616A1 (en) * 2020-03-27 2021-09-30 Gritscience Biopharmaceuticals Co., Ltd. Methods for inhibiting casein kinases
EP4126878A4 (en) * 2020-03-27 2024-07-10 Gritscience Biopharmaceuticals Co., Ltd. COMPOUNDS AS CASEIN KINASE INHIBITORS
AR122711A1 (es) * 2020-06-25 2022-09-28 Alchemedicine Inc COMPUESTO HETEROCÍCLICO COMO INHIBIDOR DE CASEÍNA QUINASA 1d Y/O QUINASA 5 TIPO RECEPTOR DE ACTIVINA

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992012154A1 (en) * 1990-12-31 1992-07-23 Fujisawa Pharmaceutical Co., Ltd. Imidazotriazine derivatives
IL110296A (en) * 1993-07-16 1999-12-31 Smithkline Beecham Corp Imidazole compounds process for their preparation and pharmaceutical compositions containing them
EP0889888A4 (en) * 1996-03-25 2003-01-08 Smithkline Beecham Corp NEW TREATMENT OF LESIONS IN THE CENTRAL NERVOUS SYSTEM
US6239279B1 (en) 1998-12-16 2001-05-29 Smithkline Beecham Corporation Synthesis for 4-aryl-5-pyrimidine imidazole substituted derivatives
GB0108770D0 (en) * 2001-04-06 2001-05-30 Eisai London Res Lab Ltd Inhibitors
IL159416A0 (en) * 2001-06-18 2004-06-01 Univ Rockefeller Regulation of neuronal function through metabotropic glutamate receptor signaling pathways
ATE428711T1 (de) * 2003-12-11 2009-05-15 Aventis Pharma Inc Substituierte 1h-pyrroloä3,2-b, 3,2-c und 2,3- cüpyridin-2-carbonsäureamide und verwandte analoga als inhibitoren von caseinkinase-i- epsilon
JO2629B1 (en) * 2004-08-19 2012-06-24 افينتيس فارما سوتيكالز انك Branched carboxylic acid amides containing thienobirol, carboxylic acid amides containing pyrolithiazole, and the like as kinase inhibitors casein epsilon
WO2006023590A1 (en) * 2004-08-19 2006-03-02 Aventis Pharmaceuticals Inc. 3-ARYLTHIOINDOLE-2-CARBOXAMIDE DERIVATIVES AND ANALOGS THEREOF AS INHIBITORS OF CASEIN KINASE Iϵ
US8101625B2 (en) * 2005-10-21 2012-01-24 Exelixis, Inc. Pyrimidinones as Casein Kinase II (CK2) modulators
EP2308866A1 (de) 2009-10-09 2011-04-13 Bayer CropScience AG Phenylpyri(mi)dinylpyrazole und ihre Verwendung als Fungizide
WO2012085721A1 (en) 2010-12-20 2012-06-28 Pfizer Inc. Novel fused pyridine compounds as casein kinase inhibitors

Also Published As

Publication number Publication date
PL2493876T3 (pl) 2014-06-30
EP2493876B1 (en) 2014-02-12
EP2493876A1 (en) 2012-09-05
KR101421852B1 (ko) 2014-07-22
JP5784620B2 (ja) 2015-09-24
US20110098272A1 (en) 2011-04-28
PT2493876E (pt) 2014-03-20
AU2010311035A1 (en) 2012-05-03
CA2777632A1 (en) 2011-05-05
HRP20140252T1 (hr) 2014-04-25
US8518944B2 (en) 2013-08-27
CN102686580A (zh) 2012-09-19
MX2012004997A (es) 2012-06-12
IL219190A0 (en) 2012-06-28
RS53246B (sr) 2014-08-29
UY32977A (es) 2011-05-31
CN102686580B (zh) 2014-09-10
JP2013509392A (ja) 2013-03-14
DK2493876T3 (en) 2014-03-10
AR078797A1 (es) 2011-12-07
WO2011051858A1 (en) 2011-05-05
HK1171220A1 (en) 2013-03-22
KR20120088759A (ko) 2012-08-08
ZA201202776B (en) 2013-06-26
ES2460065T3 (es) 2014-05-13
SI2493876T1 (sl) 2014-04-30
TW201125864A (en) 2011-08-01
CA2777632C (en) 2014-02-25
AU2010311035B2 (en) 2013-05-16

Similar Documents

Publication Publication Date Title
IN2012DN03182A (en:Method)
IN2015DN01119A (en:Method)
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
CR20200286A (es) DERIVADOS DE DIHIDRO-BENZO-OXAZINA Y DIHIDRO-PIRIDO-OXAZINA (Divisional 2014-0294)
WO2007135527A3 (en) Benzimidazolyl compounds
MX2013005833A (es) Nuevos compuestos de piridina fusionada como inhibidores de caseina quinasa.
UA99787C2 (en) Lactams as beta secretase inhibitors
IN2014MN02598A (en:Method)
PH12013500473A1 (en) Triazine-oxadiazoles
MX2012013274A (es) Novedosos derivados de la pirimidina.
MX2014012695A (es) Derivados de isoindolona.
IN2012DN01233A (en:Method)
WO2014045162A8 (en) ALKYL-SUBSTITUTED HEXAHYDROPYRANO[3,4-d] [1,3]THIAZIN-2-AMINE COMPOUNDS
MX2014000341A (es) Novedosos derivados de trifluoro-metil-oxadiazol y su uso en el tratamiento de enfermedades.
PH12014501542B1 (en) Substituted pyrrolidine -2- carboxamides
PH12014501514A1 (en) New azetidine derivatives, pharmaceutical compositions and uses thereof
MX2011012739A (es) Derivados fluorados de aminotriazol.
PH12013500007A1 (en) Piperidine derivatives and their use for the treatment of metabolic disorders
WO2010150211A3 (en) Use of derivatives of indoles for the treatment of cancer
IN2012DN01292A (en:Method)
MX2011011083A (es) Compuestos heterociclicos como inhibidores de mek.
WO2012135615A3 (en) Enopeptins, uses thereof, and methods of synthesis thereto
JO2682B1 (en) Derivatives of alkynil-8.1-naphthayridone, preparations thereof and therapeutic use thereof
MX2013008340A (es) Novedosas 4-amino-n-hidroxi-benzamidas para el tratamiento de cancer.
WO2010121675A3 (en) Thiazolyl-benzimidazoles